Detalles de la búsqueda
1.
Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of Leucine-Rich Repeat Kinase 2 G2019S Carriers: A Novel Enzyme-Linked Immunosorbent Assay-Based Method.
Mov Disord
; 35(11): 2095-2100, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32652692
2.
Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors.
Biochem J
; 473(17): 2671-85, 2016 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27474410
3.
Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease.
Neurobiol Dis
; 70: 190-203, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24969022
4.
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update.
J Parkinsons Dis
; 11(3): 891-903, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34151864
5.
The Michael J. Fox Foundation's Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson Disease.
Cells
; 9(8)2020 08 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32796584
6.
Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation.
J Vis Exp
; (157)2020 03 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32250352
7.
An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts.
J Parkinsons Dis
; 10(2): 623-629, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32007961
8.
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits.
Sci Transl Med
; 12(540)2020 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32321864
9.
The effect of LRRK2 loss-of-function variants in humans.
Nat Med
; 26(6): 869-877, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32461697
10.
The Michael J. Fox Foundation for Parkinson's Research Strategy to Advance Therapeutic Development of PINK1 and Parkin.
Biomolecules
; 9(8)2019 07 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31344817
11.
Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala.
J Neurosci
; 26(39): 9967-74, 2006 Sep 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-17005860
12.
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.
J Med Chem
; 60(7): 2983-2992, 2017 04 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-28245354
13.
Author Correction: The effect of LRRK2 loss-of-function variants in humans.
Nat Med
; 27(2): 355, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33483629
14.
Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: comparison between cocaine and a potent conventional reinforcer.
J Neurosci
; 24(20): 4723-7, 2004 May 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-15152032
15.
Effect of selective LRRK2 kinase inhibition on nonhuman primate lung.
Sci Transl Med
; 7(273): 273ra15, 2015 Feb 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-25653221
16.
A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research.
Dis Model Mech
; 6(6): 1316-24, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24046356
17.
Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs.
PLoS One
; 8(11): e80705, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24244710
Resultados
1 -
17
de 17
1
Próxima >
>>